Porton Advanced Announces FDA Acceptance of Drug Master File for Umbilical Cord Stem Cell-Derived Exosomes

The filing follows the company’s earlier cell bank DMF and gives sponsors a paired reference framework for exosome regulatory submissions.

Key Points

  • Porton Advanced announced FDA acceptance of its Drug Master File for exosomes derived from human umbilical cord mesenchymal stem cells.
  • The filing, together with a previously accepted cell bank DMF, creates a cell bank to exosome reference framework for regulatory submissions.
  • The company’s exosome platform supports multiple cell lines with scalable bioreactor manufacturing and GMP-grade delivery.

Porton Advanced, a contract development and manufacturing organization (CDMO) for advanced therapy medicinal products, announced that the FDA has accepted its Drug Master File (DMF #33274) covering exosomes derived from human umbilical cord Wharton’s jelly mesenchymal stem cells (hUC-MSCs).

A DMF is a confidential technical submission mechanism established by the FDA. Holders of raw materials, excipients, or process technologies may file proprietary technical information that downstream applicants can cross-reference in IND, BLA, or other regulatory submissions without disclosing full technical details to the sponsor.

In July 2026, Porton Advanced completed its UC-MSC cell bank DMF filing (#32973), establishing the upstream compliance cornerstone for exosome manufacturing. With the new exosome DMF filing now in place, sponsors can cross-reference both filings directly in their IND and BLA submissions. In parallel, the company’s proprietary stem cell exosome ingredient has been assigned an INCI (International Nomenclature of Cosmetic Ingredients) name, formally entering the global cosmetic ingredient dictionary.

Exosome manufacturing platform

Porton Advanced’s exosome CDMO platform supports multiple cell lines, including HEK293, MSC, K562, and iPSC, with process scalability from 2 L to 50 L bioreactors, a final product concentration of at least 1E11 particles/mL, and GMP-grade delivery within one month. To date, the platform has completed the manufacturing and delivery of multiple exosome programs for global clients, according to the company.

Porton Advanced Solutions is a subsidiary of CDMO Porton Pharma Solutions. The company has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing services from cell banking, process, and analytical method development, and cGMP production to fill and finish.

Want to keep up on regenerative medicine? Get the weekly newsletter here.

Discussion

Sign in to join the discussion.

Similar stories